Andere Sprachen Axsome Therapeutics, Inc.

Aktien

A2AA7B

US05464T1043

AXSM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
74,8 ^USD	+0,82 %		+4,31 %	-6,02 %

29.04.	Axsome Therapeutics: Phase-3-Studie zur Alzheimer-Behandlung ist risikoreich und lukrativ, so Morgan Stanley	MT
29.04.	AXSOME THERAPEUTICS, INC. : Von Morgan Stanley zum Kaufen aufgerüstet	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Axsome Therapeutics Recognizes May as Mental Health Awareness Month	01.05.
North American Morning Briefing : More Earnings -2-	30.04.
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	29.04.
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting	16.04.
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15.04.
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15.04.
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6	10.04.
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	02.04.
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01.04.
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01.04.
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	25.03.
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides	25.03.
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25.03.
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25.03.
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	25.03.
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy	25.03.
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	25.03.
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19.03.
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19.03.
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Axsome Therapeutics, Inc.

Aktien

A2AA7B

US05464T1043

AXSM

Andere Sprachen

Filter